Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Rondeau

Showing results (81-90 of 167) with videos related to

Pageof 17
Sort By:
Journal of the American Society of Nephrology : JASN|March 6, 2010
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutationsFadi Fakhouri, Lubka Roumenina, François Provot, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 20, 2008
Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejectionPierre Saint-Mezard, Céline C Berthier, Hai Zhang, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 6, 2019
Markers of graft microvascular endothelial injury may identify harmful donor-specific anti-HLA antibodies and predict kidney allograft lossKevin Louis, Alexandre Hertig, Jean-Luc Taupin, et al.
Kidney International|April 18, 2020
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatmentEric Rondeau, Marie Scully, Gema Ariceta, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 20, 2016
C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort studyAnissa Moktefi, Juliette Parisot, Dominique Desvaux, et al.
Transplantation|August 30, 2019
Immunosuppression and Graft Rejection in Living-related HLA-identical Renal Transplantation: The RADOVFULL StudyRim Ossman, Matthieu Jamme, Bruno Moulin, et al.
Transplantation|June 24, 2006
Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipientsHervé Mal, Agnès Veyradier, Olivier Brugière, et al.
Transplantation|July 1, 2010
Intragraft tubular vimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophyJesper Kers, Yi-Chun Xu-Dubois, Eric Rondeau, et al.
Haematologica|March 21, 2019
Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndromeKhalil El Karoui, Idris Boudhabhay, Florent Petitprez, et al.
BMC Nephrology|April 12, 2019
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational studyJan Menne, Yahsou Delmas, Fadi Fakhouri, et al.
Pageof 17

Showing results (81-90 of 167) with videos related to

Sort By:
Pageof 17
Journal of the American Society of Nephrology : JASN|March 6, 2010
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutationsFadi Fakhouri, Lubka Roumenina, François Provot, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 20, 2008
Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejectionPierre Saint-Mezard, Céline C Berthier, Hai Zhang, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 6, 2019
Markers of graft microvascular endothelial injury may identify harmful donor-specific anti-HLA antibodies and predict kidney allograft lossKevin Louis, Alexandre Hertig, Jean-Luc Taupin, et al.
Kidney International|April 18, 2020
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatmentEric Rondeau, Marie Scully, Gema Ariceta, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 20, 2016
C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort studyAnissa Moktefi, Juliette Parisot, Dominique Desvaux, et al.
Transplantation|August 30, 2019
Immunosuppression and Graft Rejection in Living-related HLA-identical Renal Transplantation: The RADOVFULL StudyRim Ossman, Matthieu Jamme, Bruno Moulin, et al.
Transplantation|June 24, 2006
Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipientsHervé Mal, Agnès Veyradier, Olivier Brugière, et al.
Transplantation|July 1, 2010
Intragraft tubular vimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophyJesper Kers, Yi-Chun Xu-Dubois, Eric Rondeau, et al.
Haematologica|March 21, 2019
Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndromeKhalil El Karoui, Idris Boudhabhay, Florent Petitprez, et al.
BMC Nephrology|April 12, 2019
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational studyJan Menne, Yahsou Delmas, Fadi Fakhouri, et al.
Pageof 17